Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accessible, addressed, allAzaSiteproduct, allergy, ancillary, anticipatedAzaSite, appellate, attempt, auction, banking, begun, bribery, broaden, categorized, creation, database, dealer, deferral, devaluation, entity, evidenced, excessive, exit, fact, FAS, fromAzaSite, hierarchy, indirectly, innovative, intangible, Investor, issuer, lid, maintenance, margin, matching, Moody, negligence, nonrecurring, ofAzaSiteare, ofElestatof, ofElestator, ofElestatwill, omission, opening, opposition, orderly, overstocking, paper, pharmacokinetic, pilot, Poor, predominately, Prolacriafor, purpose, quantify, question, quoted, referencing, reply, repurchase, restructure, reviewAzaSite, seizure, sellsAzaSite, show, slightly, south, studyingProlacria, subprime, suggest, suspension, toAzaSitein, toProlacriausing, unadjusted, undergone, undiscounted, unexpectedly, unobservable, unrestricted, withdrawn
Removed:
accident, accidental, adherence, advancement, Alcon, analyze, andAzaSite, andProlacria, announce, apply, arranging, assistance, AstraZeneca, attribute, automatically, averaged, award, Bausch, bilastine, biostatistical, bitter, blended, borrowing, cardiac, Chairman, CIC, cigarette, CMS, combined, compliant, congestion, conjunction, contamination, Contemporaneously, convert, core, dated, death, demonstrated, desired, disability, disposal, draft, eleven, EMEA, equitable, exceeded, exercisable, existence, Farma, FIN, forElestatand, forfeited, Genentech, Gilead, GlaxoSmithKline, HHS, hiring, history, iii, infection, infrastructure, injury, Inspector, institution, insure, intense, involuntarily, issuance, ISTA, Justice, knowledgeable, Lantibio, liable, LLC, Lomb, lump, mandatory, matter, maximum, MedPointe, Merck, multiplied, Nascent, Novagali, observed, Otsuka, Overview, parallel, participant, pediatric, peer, penalty, perennial, perfume, Pharma, pollen, pollutant, Predix, produced, productAzaSite, qui, realization, recently, recognizing, reducing, Registry, regular, relator, relying, removal, request, requested, rescinding, rhinorrhea, salary, schedule, seize, Senju, sequential, serve, settlement, SinceAzaSite, smoke, subregulatory, Sucampo, supplyAzaSite, sustained, tam, taste, taxing, test, threshold, top, trading, transition, twelve, ultimate, umbrella, unblind, unblinding, utilizing, valid, validation, Vertex, violate, Vistakon, waste
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Inspire Pharmaceuticals, Inc. Executive Change In Control Severance Benefit Plan
- 10.2 Inspire Pharmaceuticals, Inc. Change In Control Severance Benefit Plan
- 31.1 Section 302 President and CEO Certification
- 31.2 Section 302 CFO and Treasurer Certification
- 32.1 Section 906 President and CEO Certification
- 32.2 Section 906 CFO and Treasurer Certification
Related press release
ISPH similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Inspire Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2008, as filed with the Securities and Exchange Commission (the “Report”), I, Thomas R. Staab, II, Chief Financial Officer & Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 9, 2008 | /s/ Thomas R. Staab, II | |
Thomas R. Staab, II | ||
Chief Financial Officer & Treasurer (principal financial officer) |